MeReC concludes evidence for extra benefits of latest antihistamines is lacking

摘要

There is insufficient evidence to support the use of third generation antihistamines,such as desloratadine (Neoclarityn) and levocetirizine (Xyzal) over second generationb antihistamines (eg,loratadine and cetirizine),according to the latest issue of the MeReC Bulletin.